WHY IT MATTERS: As federal rescheduling moves forward, organizations that center both clinical evidence and patient experience could directly shape whether patients gain broader, safer, and more affordable access to cannabinoid therapies. CLINICAL OVERVIEW: A newly formed cannabis medicine group is working to ensure that federal policy discussions around cannabinoid therapy are rooted in scientific evidence and shaped by real patient perspectives. This effort comes at a critical moment as rescheduling conversations advance at the federal level, creating an opening to influence how cannabis is regulated, researched, and integrated into clinical care.
Takedown of Recent JAMA Cannabis Review
JAMA’s cannabis review is being treated like a verdict. It isn’t. This physician-led analysis explains what the science actually shows—and what it doesn’t—about cannabis risks, benefits, and clinical reality.
Israeli Researchers Present First Clinical Evidence That Cannabis at Microdosing Levels Relieves Pain
Syqe Medical's randomized controlled trial demonstrates for first time that THC doses measured in micrograms relieve pain without significant side effects In Summary Microdosing - the act of consuming an extremely low...